The Center for Chronic Lymphocytic Leukemia, part of the Hematologic Oncology (Blood Cancers) Treatment Center at Dana-Farber Brigham Cancer Center, promotes a comprehensive approach to the treatment of patients with chronic lymphocytic leukemia (CLL).
Our program is one of only a few dedicated CLL centers in the country. Our team of specialists has unique expertise in caring for patients with this kind of cancer, including extensive prognostic testing, tissue banking, and access to cellular therapies including stem cell/bone marrow transplant and CAR T-cell therapy, if necessary.
We are also a centralized hub for CLL research. Our team of laboratory and clinical-based investigators and physicians offers access to clinical trials of new, promising therapies. Our goal is to have a clinical trial option for patients at every stage of the disease. We offer clinical trials for newly-diagnosed CLL, relapsed/refractory CLL, as well as Richter's syndrome, a condition where CLL turns into an aggressive form of lymphoma.